G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling Research

Executive Summary: G-1 (CAS 881639-98-1) is a potent and selective agonist for the G protein-coupled estrogen receptor GPR30/GPER1, exhibiting a binding affinity of Ki ≈ 11 nM and negligible activity at ERα/ERβ even at micromolar concentrations (APExBIO). G-1 triggers rapid intracellular calcium increases (EC50 = 2 nM) and PI3K-dependent PIP3 nuclear accumulation, distinguishing it from classical estrogen receptor ligands (Wang et al. 2021). In breast cancer models, G-1 inhibits cell migration at sub-nanomolar IC50; in rat heart failure models, it reduces fibrosis and normalizes adrenergic receptor profiles. The compound is DMSO-soluble (≥41.2 mg/mL), insoluble in water/ethanol, and is best stored at -20°C for short-term use. G-1 is widely adopted as a benchmark tool in cardiovascular, endocrine, and cancer research to delineate GPR30-mediated pathways (internal review).

Biological Rationale

G protein-coupled estrogen receptor 30 (GPR30, also known as GPER1) is an integral membrane protein distinct from classical nuclear estrogen receptors (ERα, ERβ). It mediates rapid, non-genomic estrogen signaling critical in cardiovascular, immunological, and oncological physiology (Wang et al. 2021). G-1's selectivity allows researchers to dissect GPR30's contribution without confounding ERα/ERβ activation. This specificity is essential for models where rapid estrogenic effects or GPR30-targeted interventions are under investigation. The ability to rapidly manipulate intracellular signaling cascades makes G-1 an indispensable reagent in studies of hormone signaling diversity, immune regulation, and gender dimorphism in disease response (review).

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds GPR30 with high affinity (Ki ≈ 11 nM) and negligible activity at ERα or ERβ even at concentrations >1 μM (APExBIO). Upon binding, G-1 activates GPR30-coupled G proteins, leading to:

• Rapid elevation of intracellular calcium (EC50 ≈ 2 nM) in responsive cells.
• PI3K-dependent nuclear accumulation of PIP3, modulating downstream kinases and transcriptional regulators.
• Attenuation of endoplasmic reticulum stress and normalization of immune cell (CD4+ T lymphocyte) function post-injury (Wang et al. 2021).
• Inhibition of cancer cell motility by disrupting cytoskeletal rearrangement signaling.

This mechanism is reinforced by the lack of migration inhibition in breast cancer lines when using ERα or ERβ agonists alone, confirming GPR30 specificity. G-1's actions are fully reversed by GPR30 antagonists such as G15, but not by ERβ antagonists, further verifying its selectivity (contrast: comprehensive PI3K review).

Evidence & Benchmarks

• G-1 displays a binding affinity (Ki) for GPR30 of ~11 nM, with negligible displacement at ERα/ERβ up to 10 μM (APExBIO).
• In vitro, G-1 increases intracellular calcium with EC50 ≈ 2 nM (buffered cell assay, 37°C, pH 7.4) (Wang et al. 2021).
• G-1 inhibits migration in SKBr3 and MCF7 breast cancer cell lines with IC50 values of 0.7 nM and 1.6 nM, respectively (serum-free medium, 24 h migration assay) (APExBIO).
• Chronic G-1 administration (subcutaneous, 100 μg/kg/day, 4 weeks) in ovariectomized female Sprague-Dawley rats with induced heart failure reduces brain natriuretic peptide (BNP) levels, attenuates cardiac fibrosis, and improves contractility (Wang et al. 2021).
• Beneficial effects are abrogated by GPR30 antagonism (G15) but not by ERβ antagonist (DPN), confirming GPR30 mediation (Wang et al. 2021).
• G-1 restores proliferation and cytokine production in splenic CD4+ T cells post-hemorrhagic shock, associated with reduced ER stress markers (GRP78, ATF6) (Wang et al. 2021, Fig. 1).

Applications, Limits & Misconceptions

G-1 is validated in multiple preclinical research areas:

• Cardiovascular research: Models of heart failure, cardiac fibrosis, and adrenergic signaling.
• Cancer biology: Migration and signaling assays in breast, endometrial, and other GPR30-expressing cancers.
• Immunology/endocrine studies: Lymphocyte function, stress response, and rapid estrogenic modulation.

This article builds upon prior reviews (Unveiling GPR30’s Role; Decoding Selective Agonism) by providing updated, quantitative benchmarks and clarifying recent mechanistic insights from in vivo models.

Common Pitfalls or Misconceptions

• G-1 does not activate classical nuclear estrogen receptors (ERα/ERβ) at typical working concentrations; effects in such pathways are not expected.
• G-1 is insoluble in water and ethanol; improper solvent use leads to precipitation and unreliable dosing.
• Long-term (>1 week) DMSO stock storage at -20°C may result in degradation; fresh stocks are recommended for reproducibility.
• Non-specific effects at concentrations >10 μM are not well-characterized; use within established nanomolar ranges for selectivity.
• In vivo effects are best interpreted alongside GPR30 antagonist controls (e.g., G15) to confirm pathway specificity (Wang et al. 2021).

Workflow Integration & Parameters

For cell-based assays, prepare G-1 stock solutions in DMSO at >10 mM concentration, using heat and ultrasonic bath to enhance solubility. Working dilutions in culture medium should keep final DMSO below 0.1% v/v. G-1 is compatible with migration, calcium flux, and kinase activation assays. For animal studies, G-1 is typically administered subcutaneously or intraperitoneally; published protocols use doses from 10–100 μg/kg/day for 2–4 weeks. Always include appropriate vehicle and antagonist controls for data interpretation. For more on troubleshooting cell assay integration, see this technical guide, which this article updates with latest in vivo findings and solubility guidance.

Conclusion & Outlook

G-1 (CAS 881639-98-1) is a benchmark selective GPR30 agonist, enabling high-fidelity interrogation of rapid estrogen signaling in diverse disease models. Its potency, receptor selectivity, and robust in vivo efficacy make it an essential tool for cardiovascular, cancer, and immunological research. Researchers are advised to adhere to validated concentrations and storage conditions to ensure reproducibility. For product specifications and ordering, consult APExBIO (SKU B5455).